AstraZeneca (NYSE:AZN) had its price objective hoisted by Leerink Swann from $36.00 to $38.00 in a research report released on Tuesday morning. Leerink Swann currently has a market perform rating on the stock.
A number of other research analysts have also recently commented on AZN. Citigroup upgraded AstraZeneca to a buy rating in a research note on Wednesday, October 18th. Zacks Investment Research cut AstraZeneca from a hold rating to a sell rating in a research note on Wednesday, January 3rd. ValuEngine upgraded AstraZeneca from a buy rating to a strong-buy rating in a research note on Saturday. BMO Capital Markets set a $38.00 target price on AstraZeneca and gave the company a buy rating in a research note on Tuesday, October 31st. Finally, JPMorgan Chase & Co. upgraded AstraZeneca from a neutral rating to an overweight rating in a research note on Friday, December 29th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. AstraZeneca currently has a consensus rating of Hold and a consensus price target of $35.20.
Shares of AstraZeneca (NYSE:AZN) opened at $34.30 on Tuesday. AstraZeneca has a fifty-two week low of $28.09 and a fifty-two week high of $36.70. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. The firm has a market capitalization of $85,545.88, a P/E ratio of 7.89, a price-to-earnings-growth ratio of 2.64 and a beta of 0.70.
The business also recently disclosed a semiannual dividend, which will be paid on Monday, March 19th. Investors of record on Friday, February 16th will be given a dividend of $0.95 per share. This represents a yield of 5.62%. The ex-dividend date is Thursday, February 15th. AstraZeneca’s dividend payout ratio (DPR) is presently 57.81%.
Hedge funds have recently bought and sold shares of the stock. WFG Advisors LP increased its position in AstraZeneca by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after buying an additional 984 shares in the last quarter. Valeo Financial Advisors LLC bought a new position in AstraZeneca during the 3rd quarter valued at approximately $133,000. Quadrant Capital Group LLC increased its position in AstraZeneca by 18.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after buying an additional 846 shares in the last quarter. Calton & Associates Inc. bought a new position in AstraZeneca during the 4th quarter valued at approximately $181,000. Finally, Wealthcare Advisory Partners LLC bought a new position in AstraZeneca during the 3rd quarter valued at approximately $184,000. 14.79% of the stock is owned by institutional investors.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.